Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1389-1398

  Denny, Lynette ^a   Adewole, Isaac ^b   Anorlu, Rose ^c   Dreyer, Greta ^d   Moodley, Manivasan ^e   Smith, Trudy ^f   Snyman, Leon ^d   Wiredu, Edwin ^g   Molijn, Anco ^h   Quint, Wim ^h   Ramakrishnan, Gunasekaran ⁱ   Schmidt, Johannes ^j  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c UNIVERSITY OF LAGOS   (Nigeria)

^d STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^e Inkosi Albert Luthuni Central Hospital   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g UNIVERSITY OF GHANA   (Ghana)

^h DDL DIAGNOSTIC LABORATORY   (Netherlands)

ⁱ GlaxoSmithKline Pharmaceuticals Ltd   (India)

^j GSK   (Belgium)

more..

Author keywords

human papillomavirus; invasive cervical cancer; sub Saharan Africa

Indexed keywords

ADULT; AFRICA SOUTH OF THE SAHARA; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GHANA; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS PREVALENCE; HUMAN TISSUE; INVASIVE CERVICAL CANCER; MAJOR CLINICAL STUDY; MICROSCOPY; MIDDLE AGED; NIGERIA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; UTERINE CERVIX CANCER; WART VIRUS;

EID: 84891829616     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28425     Document Type: Article

References (50)

1. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-86.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
3. World Health Organization Information Centre on HPV. Human papillomavirus and related cancers-World. Summary Report Update November 15, 2010. World Health Organization webpage. Available at: http://apps.who.int/hpvcentre/ statistics/dynamic /ico/country-pdf/XWX.pdf ?CFID=5706741&CFTOKEN=92497064. Accessed July 31, 2012.
4. Denny L,. Cervical cancer treatment in Africa. Curr Opin Oncol 2011; 23: 469-74.
5. Louie KS, de Sanjose S, Mayaud P,. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health 2009; 14: 1287-302.
6. Parkin DM, Sitas F, Chirenje M, et al. Part I: cancer in Indigenous Africans-burden, distribution, and trends. Lancet Oncol 2008; 9: 683-92.
7. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
8. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
9. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
10. Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst 2011; 103: 1827-39.
11. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9.
12. de Villiers B-M,. Taxonomic classification of papillomaviruses. Papillomavirus Rep 2001; 12: 57-63.
13. American Society for Colposcopy and Cervical Pathology. Natural history of HPV. American Society for Colposcopy and Cervical Pathology webpage; 2012. Available at: http://www.asccp.org/PracticeManagement /HPV/NaturalHistoryofHPV/ tabid/5962/Default.aspx. Accessed August 22, 2012.
14. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10: 321-2.
15. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002; 109: 96-8.
16. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-84.
17. Odicino F, Pecorelli S, Zigliani L, et al. History of the FIGO cancer staging system. Int J Gynaecol Obstet 2008; 101: 205-10.
18. Quint WG, Scholte G, van Doorn LJ, et al. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J Pathol 2001; 194: 51-8.
19. van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44: 3292-8.
20. Odida M, de Sanjose S, Quint W, et al. Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis 2008; 8: 85. Available at: http://www.biomedcentral.com/content/pdf/1471-2334-8-85.pdf. Accessed October 19, 2012.
21. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
22. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35.
23. Okolo C, Franceschi S, Adewole I, et al. Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infect Agent Cancer 2010; 5: 24. Available at: http://www.infectagentscancer.com/content/pdf/ 1750-9378-5-24.pdf. Accessed October 19, 2012.
24. Ndiaye C, Alemany L, Ndiaye N, et al. Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences? Trop Med Int Health 2012; 17: 1432-40.
25. Naucler P, Da Costa FM, Ljungberg O, et al. Human papillomavirus genotypes in cervical cancers in Mozambique. J Gen Virol 2004; 85: 2189-90.
26. Castellsagué X, Klaustermeier JE, Carrilho C, et al. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. Int J Cancer 2008: 122: 1901-4.
27. Keita N, Clifford GM, Koulibaly M, et al. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009: 101: 202-8.
28. De Vuyst H, Ndirangu G, Moodley M, et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer 2012; 131: 949-55.
29. Adjorlolo-Johnson G, Unger ER, Boni-Ouattara E, et al. Assessing the relationship between HIV infection and cervical cancer in Cote d'Ivoire: a case-control study. BMC Infect Dis 2010; 10: 242.
30. Clifford G, Franceschi S,. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008; 122: 1684-5.
31. De Vuyst H, Ndirangu G, Moodley M, etal. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer 2012; 131: 949-55.
32. Singh DK, Anastos K, Hoover DR, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009; 199: 1851-61.
33. Blossom DB, Beigi RH, Farrell JJ, et al. Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. J Med Virol 2007; 79: 758-65.
34. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, et al. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer 2006; 95: 355-62.
35. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 2007; 96: 1480-3.
36. Keam SJ, Harper DM,. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008; 68: 359-72.
37. Tovar JM, Bazaldua OV,. New quadrivalent HPV vaccine developments. Postgrad Med 2008; 120: 14-6.
38. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5: 705-19.
39. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from Months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7: 1343-58.
40. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-9.
41. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
42. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40: 564-71.
43. Schwarz TF, Huang LM, Medina DM, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 Years. J Adolesc Health 2012; 50: 187-94.
44. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
45. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-66.
46. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28: 6247-55.
47. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99. Erratum in: Lancet Oncol 2012;13:89-99.
48. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39.
49. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-10. Erratum in: Lancet Oncol 2012; 13:e1.
50. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199: 926-35.